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Abstract: Modulation of the gut microbiome as a means to improve human health has recently
gained increasing interest. In this study, it was investigated whether cRG-I, a carrot-derived pectic
polysaccharide, enriched in rhamnogalacturonan-I (RG-I) classifies as a potential prebiotic ingredient
using novel in vitro models. First, digestion methods involving α-amylase/brush border enzymes
demonstrated the non-digestibility of cRG-I by host-derived enzymes versus digestible (starch/maltose)
and non-digestible controls (inulin). Then, a recently developed short-term (48 h) colonic incubation
strategy was applied and revealed that cRG-I fermentation increased levels of health-promoting
short-chain fatty acids (SCFA; mainly acetate and propionate) and lactate comparable but not
identical to the reference prebiotic inulin. Upon upgrading this fermentation model by inclusion of
a simulated mucosal environment while applying quantitative 16S-targeted Illumina sequencing,
cRG-I was additionally shown to specifically stimulate operational taxonomic units (OTUs) related to
health-associated species such as Bifidobacterium longum, Bifidobacterium adolescentis, Bacteroides dorei,
Bacteroides ovatus, Roseburia hominis, Faecalibacterium prausnitzii, and Eubacterium hallii. Finally, in a
novel model to assess host–microbe interactions (Caco-2/peripheral blood mononuclear cells (PBMC)
co-culture) fermented cRG-I increased barrier integrity while decreasing markers for inflammation.
In conclusion, by using novel in vitro models, cRG-I was identified as a promising prebiotic candidate
to proceed to clinical studies.
Keywords: prebiotic; microbiome; SCFA; colon; bifidobacteria; pectin; rhamnogalacturonan;
transepithelial electrical resistance (TEER)
1. Introduction
The colon contains a vast number of bacteria that largely impact human health. Next to preventing
pathogen colonization through secretion of antimicrobial agents [1–3], the gut microbiota is involved
in food processing, synthesis of essential vitamins and production of health-promoting short-chain
fatty acids (SCFA), including acetate, propionate and butyrate [4], upon anaerobic fermentation
of for instance dietary fibers [5]. While butyrate is an important energy source for colonocytes
with anti-inflammatory and intestinal barrier-protecting effects, propionate exerts anti-lipogenic and
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cholesterol-lowering effects in the liver [6]. In addition, as with butyrate, propionate has been reported
to exert anti-cancer effects in the colon [7,8]. Finally, acetate is used in the liver as a substrate for
cholesterol and fatty acid synthesis [9,10]. In terms of composition, the human gut microbiome mainly
consists of the Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, Fusobacteria, and Verrucomicrobia
phyla [11]. Despite having provided key insights, many studies have been limited to (descriptive)
analysis of fecal samples as in situ samples from the site of fermentation are difficult to obtain. To allow
in-depth research focusing on not only luminal, but also gut wall-associated mucosal microbes, a novel
in vitro model (M-SHIME®; Mucosal Simulator of the Human Intestinal Microbial Ecosystem) was
recently developed as a complementary in vitro tool [12]. In this model, the mucosal microbiota was
enriched with butyrate-producing Clostridium cluster XIVa members, correlating with in vivo findings
from biopsies [13–18].
Modulation of the human gut microbiome as a route to improve human health has gained a lot of
interest over recent years. Prebiotics are defined as non-digestible food ingredients that selectively
stimulate health-promoting bacteria [19]. A key feature of prebiotics is their resistance to upper
gastro-intestinal digestion so that they reach the colon where they are fermented by the gut microbiome.
To assess potential digestibility of polysaccharides, two complementary enzyme sources are to be
considered, i.e., amylases [20] and brush border enzymes [21]. α-amylase is present in both saliva
and pancreatic juice and can liberate maltose from starch [20]. Furthermore, sucrase-isomaltase and
maltase-glycoamylase, collectively known as α-glucosidases, are complexes consisting of 4 enzymes
that release glucose from oligosaccharides present at the intestinal brush border [21]. These host-derived
enzymes jointly digest carbohydrates and hence their specificity determines whether carbohydrates
reach the colon and can exert prebiotic effects. Although critical to the definition of potential prebiotic
ingredients, studies confirming their indigestibility are scarce.
Fructans, such as fructooligosaccharides (FOS) and inulin are considered to be “gold standard”
prebiotics, with human clinical trials supporting their beneficial effect in acute and chronic diseases such
as obesity and type 2 diabetes (T2D), allergy, inflammatory bowel disease (IBD), Traveler’s diarrhea and
constipation (an overview is given in [19]). As many health-related species belong to the Bifidobacteriaceae,
prebiotic potential has often been related to an increase of this family. There is however increasing
understanding that prebiotics can be fermented by a wider range of gut microbes. Inulin can e.g., also
be rapidly fermented by health-promoting Bacteroidaceae members, such as Bacteroides caccae [22,23].
Currently, there is growing interest to develop novel prebiotics. A specific class of candidates includes
pectin-derived polysaccharides enriched in the branched part of pectin, i.e., the rhamnogalacturonan-I
(RG-I) domains, which can be extracted from several food crops including carrot. The backbone of
RG-I is a repeating unit of the disaccharide [-2)-α-L-rhamnose-(1,4)-α-D-galacturonic acid-(1] and
RG-I side-chains consist of galactans (β-1,4-D-galactose (D-Gal) units) and/or arabinans (α-1,5-linked
L-arabinofuranose (L-Araf) units with additional L-Araf side-chains), with varying length and
composition [24]. Given their structural complexity, RG-I extracts would require fermentation by
a consortium of gut microbes with complementary metabolic capabilities [25].
Gut microbial modulation is linked to human health with the concept of a “leaky gut” having
gained attention, not only in the context of inflammatory bowel disease, but also in a wider range of
psychological and metabolic disorders [26]. Increased intestinal epithelial permeability would allow
translocation of bacterial cell wall components, metabolites, or even whole bacteria into the systemic
circulation, hence contributing to inflammation and injury, not only in the gut but also in remote organs
such as the liver and the brain. Host–microbe interaction studies are increasingly being performed
to document this. As an example, microbial fermentation samples can be combined with a human
co-culture model [27], including intestinal epithelial cells (Caco-2) and monocytes (THP-1) [28], which
demonstrated the gut barrier protective effects together with immuno-modulatory capacity of several
prebiotics, including arabinoxylo-oligosaccharides (AXOS) [29], inulin, FOS [30] and a dried yeast
fermentate [31]. Despite its usefulness, this model has the limitation that monocytes are only one of the
cell lineages involved in the immune response. Therefore, using a co-culture model including Caco-2
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cells and peripheral blood mononuclear cells (PBMCs), containing lymphocytes (T-cells, B-cells, and
NK-cells), monocytes and dendritic cells [32], could increase the in vivo relevance.
Therefore, the present study investigated whether a carrot-derived RG-I enriched extract (cRG-I)
classifies as a potential prebiotic ingredient using a combination of novel in vitro models (Figure 1).
First, potential digestion by amylase/brush border enzymes was investigated (Test 1). Then, a recently
developed short-term colonic incubation strategy was applied [29] to assess the potential impact of cRG-I
on microbial metabolic activity including inulin as a reference (Test 2). Subsequently, after upgrading the
fermentation model by inclusion of a simulated mucosal microbiota [12], more in-depth fermentation
tests were performed to characterize the prebiotic potential of two carrot RG-I formulations that differed
in absence (cRG-I) or presence of low molecular weight carbohydrates (cRG-I+LMWC) (Test 3). To obtain
detailed insights in modulation of microbial composition, a novel technique was used where flow
cytometry was combined with 16S-targeted Illumina sequencing to obtain quantitative information at
high phylogenetic resolution [33]. Finally, fermentation samples were screened for potential beneficial
effects on gut barrier integrity and immune modulation in a newly optimized Caco-2/PBMC co-culture
model (test 4).
Figure 1. Schematic representation of the integrated in vitro approach to investigate the prebiotic
potential of cRG-I (carrot-derived rhamnogalacturonan-I). First, potential digestion of cRG-I by
amylase/brush border enzymes was investigated (Test 1). In Test 2, short-term colonic batch incubations
were used to assess the prebiotic potential on microbial metabolic activity of cRG-I compared to inulin.
In Test 3, the prebiotic potential of two formulations that differed in absence (cRG-I) or presence
of low molecular weight carbohydrates (cRG-I+LMWC) was assessed in both conventional luminal
incubations (L) and incubations including a mucosal compartment (M). Samples were collected to
evaluate the effect of the test products on microbial activity, community composition and on intestinal
permeability and immunity (Test 4, Caco-2/PBMC co-culture model).
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2. Materials and Methods
2.1. Products
The two carrot RG-I preparations used in this study (cRG-I [34] and cRG-I+LMWC) were
provided by NutriLeads (Wageningen, The Netherlands). Both are pectin-derived polysaccharides and
cRG-I+LMWC differs from cRG-I by containing small size sugars, mainly mono- and disaccharides
of galactose, glucose, and uronic acids. Pectin is a linear homogalacturonan (HG) interspaced with
branched rhamnogalacturonan (RG) regions. HG consists of α-1,4-linked D-galacturonic acid (GalA)
monomers while the RG-I backbone is a repeating unit of the disaccharide [-2)-α-L-rhamnose-1,4)-
(α-D-galacturonic acid-(1]. The RG-I backbone is decorated with galactans (β-1,4-D-galactose (D-Gal)
units) and/or arabinans (α-1,5-linked L-arabinofuranose (L-Araf) units [25]. Inulin (Orafti® HP, 100%
inulin, 0% sweetness level, average DP ≥ 23) was generously provided by Beneo GmbH (Mannheim,
Germany).
2.2. Digestion by Amylase and Brush Border Enzymes (Test 1)
Digestion with amylase was performed as described previously [20]. Briefly, cooked starch
(positive control), inulin (negative control) and cRG-I were suspended in distilled water at 15 g/L.
A stock solution of 1500U α-amylase/mL (10080, Sigma–Aldrich, Bornem, Belgium) was prepared and
added to the substrates to simulate the small intestinal phase, while respecting the ratio of units of
amylase versus amount of test product according to the Infogest consensus method (1300 units per
gram test product [20]). Samples were incubated for 60′ at 37 ◦C. Furthermore, digestion with brush
border enzymes was performed as previously described in [21]. Briefly, intestinal aceton powder from
rat (Sigma–Aldrich, Bornem, Belgium) was dissolved in 0.9% NaCl solution, vortexed, and sonicated.
15 g/L stock solutions of inulin (negative control) and maltose (positive control) were prepared in
sodium phosphate buffer (pH 7), while cRG-I was prepared in distilled water. 100 µL enzyme solution
and 50 µL substrates were mixed with 100 µL phosphate buffer and incubated for 90′ at 37 ◦C. High
Performance Anion Exchange Chromatography with Pulsed Amperometric Detection (HPAEC-PAD)
was used to measure rhamnose, arabinose, galactose, fructose, glucose, maltose, and galacturonic acid
in both digestion experiments. All tests were done in technical triplicate.
2.3. Short-Term Colonic Batch Incubations (Tests 2 and 3)
Short-term colonic incubations were performed as described in [29]. Briefly, freshly collected fecal
material of a healthy human donor (f, 26) was collected and after preparation of an anaerobic fecal slurry
inoculated at 10 vol% in a sugar-depleted nutritional medium containing 5.2 g/L K2HPO4, 16.3 g/L
KH2PO4, 2.0 g/L NaHCO3 (Chem-lab NV, Zedelgem, Belgium), 2.0 g/L Yeast Extract, 2.0 g/L pepton
(Oxoid, Aalst, Belgium), 1.0 g/L mucin (Carl Roth, Karlsruhe, Germany), 0.5 g/L L-cystein and 2.0 mL/L
Tween80 (Sigma–Aldrich, Bornem, Belgium). When mucin-coated carriers were added to the reactors
during Test 3, 1.0 g/L mucin was omitted from the nutritional medium. Five mucin-coated carriers were
added per reactor after being prepared according to Van den Abbeele et al. (2013) [12]. Test products
were dosed at 5 g/L and reactors were anaerobically incubated at 37 ◦C for 48 h. All experiments were
performed in technical triplicate.
2.4. Microbial Metabolic Activity (Tests 2 and 3)
Samples were collected upon 0 h, 6 h, 24 h, and 48 h of incubation from each colon reactor.
Gas production was measure with a pressure meter (Hand-held pressure indicator CPH6200; Wika, Echt,
The Netherlands) and pH measurements were performed with a Senseline pH meter F410 (ProSense,
Oosterhout, The Netherlands). Total SCFA were determined as the sum of acetate, propionate, butyrate
and branched-chain fatty acids (bCFA; isobutyrate, isovalerate and isocaproate) levels, and were
measured as described previously [35]. Lactate production was assessed with a commercially available
kit (R-Biopharm, Darmstadt, Germany), according to manufacturer’s instructions.
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2.5. Microbial Community Composition (Test 3)
After 48 h of incubation, samples from both lumen and mucus were collected for analysis
of the microbial community composition through quantitative polymerase chain reaction (qPCR)
and 16S-targeted Illumina sequencing. DNA was isolated as described in [36] from either 1 mL
luminal samples or 0.1 g mucus samples. Subsequently, qPCR was performed on a QuantStudio
5 Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). Each sample was run in
technical triplicate and outliers with more than 1 CT difference were omitted. The qPCRs were
performed as described previously for the following groups: Lactobacillus spp. [37], Bifidobacterium
spp. and Eubacterium rectale/Clostridium coccoides [38], Akkermansia muciniphila [39], Bacteroidetes [40],
Enterobacteriaceae [41], Faecalibacterium prausnitzii [42], Roseburia and Eubacterium hallii [43]. In addition,
microbiota profiling was performed using 16S-targeted Illumina sequencing analysis (LGC genomics
GmbH, Berlin, Germany) as described in [44] to obtain proportional abundances (%) at different
phylogenetic levels (phylum, family, and operational taxonomic unit (OTU) level). Briefly, library
preparation and sequencing were performed on an Illumina MiSeq platform with v3 chemistry. The 16S
rRNA gene V3-V4 hypervariable regions were amplified using primers 341F (5′-CCT ACG GGN GGC
WGC AG-3′) and 785Rmod (5′-GAC TAC HVG GGT ATC TAA KCC-3′) [45]. As described in [46,47],
the 16S-targeted sequencing analysis was adapted from the MiSeq protocol for read assembly and
cleanup using the mothur software (v. 1.39.5) as follows: (1) reads were assembled into contigs,
(2) alignment-based quality filtering was performed by alignment to the mothur-reconstructed SILVA
SEED alignment (v. 123), (3) chimeras were removed, (4) taxonomy was assigned via a naïve Bayesian
classifier [48] and RDP release 14 [49] and (5) contigs were clustered into OTUs at 97% sequence
similarity. Sequences classified as Eukaryota, Archaea, Chloroplasts, Mitochondria, and non-classified
sequences were also removed. For each OTU, representative sequences were selected as the most
abundant sequence within that OTU. Finally, the obtained high-resolution proportional phylogenetic
information (i.e., proportional abundances (%)) was combined with an accurate quantification of total
bacterial cells via flowcytometry to obtain quantitative data at phylum, family, and OTU level. This was
done by multiplying the proportional abundances with absolute cell numbers (cells/mL) obtained
via flowcytometry. For flowcytometry analysis, 10-fold serial dilutions were prepared in Dulbecco’s
Phosphate-buffered Saline (DPBS) (Sigma–Aldrich, Bornem, Belgium) of all samples and stained with
0.01 mM SYTO24 (Life Technologies Europe, Merelbeke, Belgium) for 15′ at 37 ◦C in the dark. Samples
were analyzed on a BD Facsverse (BDBiosciences, Erembodegem, Belgium) using the high-flow-rate
setting and bacteria were separated from medium debris and signal noise by applying a threshold
level of 200 on the SYTO channel. Flowcytometry data were analyzed using FlowJo, version 10.5.2.
2.6. Caco-2/PBMC Co-Culture Model (Test 4)
Caco-2 cells (HTB-37; American Type Culture Collection) were cultured in Dulbecco’s Modified
Eagle Medium (DMEM) containing glucose and glutamine (Sigma–Aldrich, Bornem, Belgium)
and supplemented with HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) and 20% (v/v)
heat-inactivated (HI) fetal bovine serum (FBS) (Gibco, Life Technologies Europe, Merelbeke, Belgium).
PBMCs were isolated from buffy coats of healthy donors (Red Cross, Ghent, Belgium) using
LymphoprepTM (STEMCELL technologies SARL, Grenoble, France). In brief, blood was collected and
diluted (1/5, v/v) in DPBS without Ca/Mg (Sigma–Aldrich, Bornem, Belgium). Then, LymphoprepTM
solution was added and samples were centrifuged at 1027× g for 20′ at room temperature (RT) to
separate the mononuclear cells (MNCs) and red blood cells by density-gradient centrifugation. MNCs
were collected and washed 3 times with ice-cold DPBS (340× g, 7′). Aliquots of PBMCs were frozen in
liquid nitrogen. Baseline IL-8 levels were determined by enzyme-linked immunosorbent assay (ELISA)
(Invitrogen, Thermo Fisher Scientific, Merelbeke, Belgium) to eliminate donors with high basal cytokine
levels. For experiments, Caco-2 cells were seeded on 24-well semipermeable inserts (0.4 µm pore size)
at a density of 1 × 105 cells/insert and cultured for 14 days until a functional cell monolayer with a
transepithelial electrical resistance (TEER) of more than 300 Ωcm2 was obtained. PBMCs, stimulated
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with 2.5 µg/mL pokeweed mitogen (PWM) were added to the basolateral chamber at a concentration
of 1 × 106 cells/well. PBMCs without PWM stimulation were included as negative control. At the same
time, colonic suspensions (filter-sterilized (0.22 µm) and diluted 1/5 (v/v) in culture medium) or 5 mM
sodium butyrate (NaB) (Sigma–Aldrich, Bornem, Belgium) were added to the Caco-2 cells at the apical
side. Caco-2 cells were also treated with medium as negative control. Cells were incubated for 48 h at
37 ◦C in a humidified atmosphere of air/CO2 (95:5, v/v). TEER was measured at start (0 h timepoint)
and after 48 h of incubation using a Millicell ERS2 Voltohmmeter (EMD Millipore, Sigma–Aldrich,
Bornem, Belgium). All 48 h values were normalized to their own 0 h value after subtraction of the
empty insert value and are presented as percentage of initial value. In addition, basolateral supernatant
was collected after 48 h of incubation for cytokine analysis. Human IFN-γ, IL-17A, IL-21, IL-22, IL-4,
and IL-9 levels were determined by Luminex® multiplex (Procartaplex, Invitrogen, Thermo Fisher
Scientific) and IL-10 levels were measured by ELISA (Invitrogen, Thermo Fisher Scientific), according
to the manufacturers’ instructions. All experiments were performed in triplicate.
2.7. Statistics
To evaluate differences in microbial metabolites (tests 2 and 3) and microbial community
composition at phylum level between blank and treatment incubations (Test 3), a two-way analysis of
variance (ANOVA) with Dunnett’s multiple comparisons test was performed. Statistically significant
differences between the blank and treatments are presented by (*, ∆0 h–6 h), ($, ∆6 h–24 h) or (#, ∆24
h–48 h). 1 sign = p < 0.05, 2 signs = p < 0.01, 3 signs = p < 0.001 and 4 signs = p < 0.0001. Statistical
analysis was performed with the GraphPad Prism software (version 8.3.0, San Diego, USA). To evaluate
differences in microbial community composition at family and OTU level between blank and treatment
incubations (Test 3), a Student’s t-test was performed (Excel Software). Differences were found
significant if p < 0.05. To evaluate differences between PWM+ and PWM- or NaB in the Caco-2/PBMC
co-culture assay (Test 4), an ordinary one-way ANOVA with Dunnett’s multiple comparisons test
was performed; while differences between blank and treatment incubations were assessed with an
ordinary one-way ANOVA with Tukey’s multiple comparisons test. Statistically significant differences
are presented by (*). (*) = p < 0.05, (**) = p < 0.01, (***) = p < 0.001 and (****) = p < 0.0001. Statistical
analysis was performed with the GraphPad Prism software (version 8.3.0, San Diego, USA).
3. Results
3.1. cRG-I is Resistant to Digestion in the Human Upper Gastro-Intestinal Tract (GIT) (Test 1)
One of the characteristics of a prebiotic is its non-digestibility by host enzymes upon passage along
the upper GIT [19]. First, upon exposure to amylase, the positive control cooked starch was readily
degraded into maltose, demonstrating its known digestibility (Figure 2A), while the negative control
inulin and also cRG-I were not digested to any of the simple sugars measured. Likewise, maltose was
digested by brush border enzymes into glucose (Figure 2B), in contrast to the negative control inulin
and cRG-I. Therefore, cRG-I can be considered to be a polysaccharide that likely escapes upper GIT
digestion in vivo thereby reaching the colon where it could be fermented by the gut microbiota.
3.2. Effect of cRG-I on Microbial Metabolic Activity in Short-Term Colonic Incubations (Test 2)
Short-term colonic incubations were performed to investigate the potential prebiotic effect of cRG-I
on microbial activity, including inulin as a positive control. A first indication of cRG-I fermentation
by the gut microbiota followed from the significant pH decrease and enhanced gas production
during the first 6 h of incubation (∆0–6 h) versus the blank (Figure 3A,B). These changes were even
stronger compared to inulin. Between 6 h and 24 h, cRG-I significantly and strongly decreased pH
while increasing gas production. pH decreases and gas production were more excessive for inulin.
Finally, during the 24 h to 48 h time interval, relatively stable pH values and gas levels indicated
substrate depletion.
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Figure 2. Digestion of cRG-I (carrot-derived rhamnogalacturonan-I) by amylase (A) and brush border
enzymes (B) versus inulin, cooked starch, and maltose. Blank incubations containing all reagents in
absence of a substrate were included. Average (± st. dev.) concentrations of different monosaccharides
and maltose were measured by High Performance Anion Exchange Chromatography (HPAEC) (n = 3).
Figure 3. Effect of fermentation of cRG-I on microbial metabolic activity in short-term colonic
incubations. Average changes (± st. dev.) in pH (A), gas production (B), total short-chain fatty acids
(SCFA) (C), acetate (D), propionate (E), butyrate (F), branched CFA (bCFA) (G) and lactate (H) levels
between 0 and 6 h (light gray), 6 h and 24 h (dark gray) and 24 h and 48 h (stripes) upon dosing cRG-I
and inulin to the gut microbiota versus a blank incubation (n = 3). Statistically significant differences
between blank and treatments for different time intervals are presented by * for ∆0 h–6 h, $ for ∆6 h–24
h or # for ∆24 h–48 h. (*, $, #) = p < 0.05, (**, $$, ##) = p < 0.01, (***, $$$, ###) = p < 0.001 and (****, $$$$,
####) = p < 0.0001.
Upon measuring lactate and SCFA production, acids responsible for aforementioned pH changes
were elucidated. During the 0 h to 6 h time interval, cRG-I, but not inulin, significantly increased
the production of total SCFA (Figure 3C) which resulted from more strongly elevated acetate levels
(Figure 3D) next to significant raises in lactate production for cRG-I (Figure 3H). Furthermore, both
treatments strongly augmented total SCFA production during the 6 h to 24 h time interval (merely
due to increases in acetate and propionate (Figure 3D,E)), which were more profound for cRG-I
compared to inulin. cRG-I, unlike inulin, also stimulated butyrate production during this interval
(Figure 3F), which coincided with lactate consumption. Finally, during the 24 h to 48 h time interval,
total SCFA production only increased upon treatment with inulin, which was related to increases of
acetate, propionate, and butyrate levels, thus indicating slower fermentation of inulin versus cRG-I
(Figure 3C–F). The stimulation of butyrate by inulin between 24–48 h correlated with the consumption
of lactate during this time interval. Overall, lactate was entirely consumed at the end of the incubations,
suggesting optimal conversion to propionate and/or butyrate [50]. Finally, bCFA result from protein
fermentation by the gut microbiota [51,52], which is associated with detrimental health effects [51].
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bCFA were mainly produced during the 6 h to 48 h time frame (Figure 3G), with both cRG-I and
especially inulin significantly decreasing bCFA production.
3.3. Effect of cRG-I and cRG-I +LMWC on Microbial Metabolic Activity in Short-Term Colonic Incubations
with or without a Mucosal Compartment (Test 3)
An in-depth characterization of the effects of cRG-I on microbial metabolic activity (Figure 4A–H)
was performed by testing both cRG-I and a modified formulation containing small sugars (cRG-I
+LMWC), dosed to colonic incubations including solely a luminal (L) or additionally also a mucosal
(M) environment. In consistency with Test 2, cRG-I significantly decreased the pH during the first
6 h of incubation versus the blank due to enhanced acetate and lactate levels. Furthermore, the main
fermentation occurred between 6 h and 24 h with strong increases in gas production and further
decreases of pH due to stimulation of acetate, propionate, and to a lesser extent butyrate. The latter
could again be linked to coinciding lactate consumption. Finally, the absence of marked changes of
aforementioned parameters between 24 h and 48 h again indicated substrate depletion, while bCFA
were significantly decreased thus illustrating the potential protective effects of cRG-I against toxic
by-products of proteolytic fermentation.
cRG-I+LMWC exerted similar effects on microbial activity versus cRG-I with some minor
differences. These included a more profound pH decrease for cRG-I+LMWC during the first 6 h of
incubation due to enhanced acetate and lactate levels. Furthermore, acetate and propionate production
between 6–24 h was less strongly increased with cRG-I+LMWC compared to cRG-I.
Overall, while no major differences were observed between incubations with or without mucosal
environment, inclusion of mucus beads led to a tendency to higher gas production, with higher
butyrate levels for the blank incubation, suggesting colonization of butyrate-producing bacteria on the
mucin-coated carriers.
3.4. Effect of cRG-I and cRG-I +LMWC on Microbial Community Composition in Short-Term Colonic
Incubations with or without a Mucosal Compartment (Test 3)
The data at phylum level are presented both as proportional (Figure 5A) and absolute values
(Figure 5B). This demonstrated that for the luminal microbiota, quantitative data revealed greater
insight in the true compositional changes since both cRG-I and cRG-I+LMWC largely increased total
cell numbers. In contrast, due to the large variation in total cell numbers within identical replicates for
the mucosal microbiota resulting in large variations of quantitative numbers, proportional abundances
were preferred to draw conclusions on modulation of the mucosal microbiota. Therefore, abundances
at the family level are presented as absolute data for the luminal microbiota, whereas they are presented
as proportional values for the mucosal compartment (Table 1). Furthermore, proportional abundance
of the 25 most abundant OTUs and 7 additional OTUs affected by at least one of the treatments are
shown in Supplementary Table S1 to get insights at the highest phylogenetic resolution possible.
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Figure 4. Effect of fermentation of cRG-I and cRG-I+LMWC on microbial metabolic activity in
short-term colonic batch simulations in absence or presence of a mucosal compartment. Average
changes (± st. dev.) in pH (A), gas production (B), total short-chain fatty acids (SCFA) (C), acetate (D),
propionate (E), butyrate (F), branched CFA (bCFA) (G) and lactate (H) levels between 0 and 6 h (light
gray), 6 h and 24 h (dark gray) and 24 h and 48 h (stripes) upon dosing cRG-I and cRG-I + LMWC to
the gut microbiota versus a blank incubation (n = 3). Statistically significant differences between the
blank and treatments for different time intervals are presented by * for ∆0 h–6 h, $ for ∆6 h–24 h or # for
∆24 h–48 h). (*, $, #) = p < 0.05, (**, $$, ##) = p < 0.01, (***, $$$, ###) = p < 0.001 and (****, $$$$, ####) =
p < 0.0001. L = colonic incubations only simulating lumen; M = incubations simulating both lumen
and mucus.
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Figure 5. Effect of fermentation of cRG-I and cRG-I+LMWC on microbial community composition
at phylum level in short-term colonic incubations in absence or presence of a mucosal compartment.
Average (± st. dev.) proportional (%) (A) and absolute (16S gene copies/mL) (B) abundance of the
different phyla in the original (diluted) inoculum (INO) and after 48 h of incubation upon dosing of
cRG-I and cRG-I+LMWC versus a blank control (n = 3). Statistically significant differences between the
blank and treatments are presented by *. (*) = p < 0.05, (**) = p < 0.01, (***) = p < 0.001 and (****) =
p < 0.0001. L = colonic incubations only simulating lumen; M = incubations simulating both lumen
and mucus.
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Table 1. Effect of fermentation of cRG-I and cRG-I+LMWC on microbial composition at family level in short-term colonic incubations in absence or presence of a
mucosal compartment. Average proportional (%) (mucus) and absolute (16S gene copies/mL) (lumen) abundance of the different bacterial families in the original
(diluted) inoculum and after 48 h of incubation upon dosing cRG-I and cRG-I +LMWC versus a blank control (n = 3). Statistically significant differences between the
blank and treatments are indicated in bold (p < 0.05). Upon reaching statistically significant differences, highest values are underlined. Values indicated in italicsy are
strongly increased, although not significant. L = colonic incubations only simulating lumen; M = incubations simulating both lumen and mucus.




blank cRG-I cRG-I+LMWC blank cRG-I cRG-I+LMWC blank cRG-I cRG-I+LMWC
Actinobacteria
Bifidobacteriaceae 7.28 7.18 8.68 8.28 6.89 8.63 8.26 0.2% 6.4% 1.2%
Coriobacteriaceae 8.22 6.60 6.39 6.88 6.25 6.36 6.80 0.0% 0.0% 0.0%
Eggerthellaceae 6.56 7.72 7.40 7.22 7.49 7.29 7.09 0.1% 0.0% 0.0%
Bacteroidetes
Bacteroidaceae 7.94 8.63 9.60 9.50 8.52 9.65 9.45 20.1% 9.1% 8.5%
Marinifilaceae 6.23 6.12 6.36 6.04 6.46 6.43 6.25 0.1% 0.0% 0.0%
Muribaculaceae 6.10 7.02 6.73 6.15 6.78 6.56 6.03 0.1% 0.0% 0.0%
Prevotellaceae 6.74 <LOQ 7.04 6.04 5.48 6.55 6.15 0.0% 0.0% 0.0%
Rikenellaceae 7.94 6.85 7.02 6.60 6.57 6.83 6.68 0.1% 0.0% 0.1%
Tannerellaceae 6.19 7.70 7.35 7.05 7.58 7.42 7.24 0.1% 0.0% 0.0%
Firmicutes
Christensenellaceae 7.58 7.06 7.14 6.66 6.82 6.94 6.75 0.0% 0.0% 0.0%
Clostridiaceae cluster I 6.15 5.96 <LOQ 5.95 6.40 5.94 6.17 41.7% 2.1% 1.8%
Erysipelotrichaceae 7.41 6.93 7.32 7.33 7.07 7.55 7.81 1.1% 1.0% 1.4%
Clostridiaceae cluster XI <LOQ 6.27 6.58 6.39 6.36 6.48 6.69 0.0% 0.0% 0.0%
Clostridiaceae cluster XIII 6.43 6.45 6.14 <LOQ 6.73 6.16 6.09 0.0% 0.0% 0.0%
Lachnospiraceae 8.59 8.65 8.93 8.57 8.51 8.73 8.58 28.3% 74.0% 79.1%
Peptococcaceae 6.53 6.36 6.07 5.85 6.16 <LOQ 5.69 0.0% 0.0% 0.0%
Peptostreptococcaceae 6.45 6.15 6.70 6.43 5.95 7.16 7.30 0.0% 0.0% 0.0%
Ruminococcaceae 8.64 8.38 8.83 8.30 8.34 8.72 8.49 4.1% 3.0% 1.5%
Streptococcaceae 6.37 <LOQ 6.70 8.14 5.26 5.80 8.17 0.1% 1.0% 0.5%
Veillonellaceae 7.77 7.67 8.45 8.01 7.51 8.31 8.16 0.2% 0.2% 0.2%
Proteobacteria
Burkholderiaceae 5.18 6.78 6.83 6.32 6.74 6.60 6.41 0.0% 0.0% 0.0%
Desulfovibrionaceae 6.19 6.26 6.73 6.75 6.15 6.80 6.93 0.0% 0.0% 0.0%
Enterobacteriaceae 6.03 9.10 9.32 9.35 8.90 9.29 9.45 2.8% 2.8% 5.1%
Verrucomicrobia Akkermansiaceae 7.63 7.91 7.55 7.71 8.46 8.67 8.64 0.6% 0.2% 0.4%
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First, upon comparing the luminal and mucosal microbiota, it followed that the Firmicutes phylum
was enriched in the mucosal compartment, while Actinobacteria, Proteobacteria and Verrucomicrobia
were enriched in the lumen (Figure 5A), in accordance to what has been published for the M-SHIME®
model [12]. At family level, the mucosal Firmicutes enrichment was due to a marked enrichment in
Clostridiaceae cluster I and Lachnospiraceae (Table 1). At OTU level, this was reflected by an enrichment
of OTU14 (related to Clostridium butyricum), OTU10 (related to Clostridium tertium), OTU8 (related
to Clostridium paraputrificum), OTU12 (related to Ruminococcus torques), OTU3 (related to Roseburia
hominis) and OTU19 (related to Ruminococcus lactaris) (Table S1). Furthermore, the decreased mucosal
levels of Actinobacteria, Proteobacteria and Verrucomicrobia were solely related to a decreased mucosal
colonization of members of the Eggerthellaceae, Enterobacteriaceae, and Akkermansiaceae. Another overall
finding of the in vitro model was that the luminal microbiota of blank incubations in absence and
presence of a mucosal environment were highly similar. The introduction of mucin beads only resulted
in an enrichment of the luminal Verrucomicrobia levels (Figure 5A,B). At family level, this was due to an
increased luminal abundance of Akkermansiaceae (+0.55 log copies/mL) (Table 1).
With respect to treatment effects in the lumen, cRG-I and cRG-I+LMWC both increased the absolute
levels of Actinobacteria, Bacteroidetes and Proteobacteria compared to the blank (Figure 5B). Although
the increase of Actinobacteria and Bacteroidetes was strongest for cRG-I, the increase in Proteobacteria
was strongest for cRG-I+LMWC. cRG-I additionally increased luminal Firmicutes levels. The luminal
increase in Actinobacteria by cRG-I was due to a significant increase of OTUs related to Bifidobacterium
longum (OTU7) and Bifidobacterium adolescentis (OTU21) (Table S1), thus also strongly increasing
Bifidobacteriaceae levels upon cRG-I treatment (Table 1). Furthermore, cRG-I also stimulated mucosal
Bifidobacteriaceae, mostly due to the stimulation of the Bifidobacterium longum-related OTU7. The luminal
Bacteroidetes increase upon treatment with both products was due to the stimulation of the Bacteroidaceae
and Prevotellaceae families, with again the highest levels being reached for cRG-I. At OTU level, a wide
spectrum of Bacteroidaceae members were stimulated upon dosing both cRG-I and cRG-I+LMWC,
including OTUs related to B. ovatus (OTU22), B. plebeius (OTU6), B. xylanisolvens (OTU18) and especially
B. dorei (OTU2). As a remark, a decrease in abundances of OTUs related to B. caccae (OTU13), B. fragilis
(OTU11) and B. uniformis (OTU17) upon cRG-I and cRG-I+LMWC treatment was noted, but these
decreases were less profound compared to observed increases in other OTUs. The increased abundance
in Proteobacteria related to an enrichment of Desulfovibrionaceae and Enterobacteriaceae, which was most
pronounced upon dosing of cRG-I+LMWC. Finally, the luminal increase in Firmicutes with cRG-I and
cRG-I+LMWC was due to increased levels of Erysipelotrichaceae, Peptostreptococcaceae, Streptococcacae,
Ruminococcaceae, and Veillonellaceae. The enrichment in Streptococcacae was most pronounced upon
dosing cRG-I+LMWC and linked to an increase in OTU26 (related to Streptococcus aginosus). In contrast,
the increase in Veillonellaceae was more pronounced upon dosing of cRG-I and was attributed to an
increase in OTU9 (related to Dialister succinatiphilus). Within the Ruminococcaceae, two OTUs related
to Faecalibacterium prausnitzii (i.e., OTU83 and OTU5) increased upon cRG-I, while only OTU5 was
stimulated by cRG-I+LMWC and this to a lesser extent.
In the mucosal compartment, both treatments slightly increased Firmicutes, while decreasing
Bacteroidetes levels (Figure 5A). Both cRG-I and cRG-I+LMWC strongly enriched Lachnospiraceae
(Table 1), due to a marked stimulation of OTU3 (related to Roseburia hominis) that increased from 9.8%
in the blank control incubations to 64.3% and 74.2%, respectively (Table S1). Although both treatments
also significantly increased the proportion of Streptococcacae in the mucosal environment, only cRG-I
increased mucosal Actinobacteria abundances.
To confirm several of the above-mentioned observations obtained through 16S-targeted Illumina
sequencing, qPCRs on specific bacterial groups of interest were performed (Supplementary Table S2).
This confirmed the key aforementioned conclusions obtained through 16S-targeted Illumina sequencing
including that both cRG-I and cRG-I+LMWC stimulated levels of (i) luminal/mucosal Bifidobacteriaceae
(and not Lactobacillaceae); (ii) luminal Bacteroidetes; (iii) luminal Faecalibacterium prausnitzii; (iv) mucosal
Roseburia (and Eubacterium rectale/Clostridium coccoides group to which it belongs); while not affecting
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Akkermansia muciniphila. In addition, both products, but mostly cRG-I+LMWC, increased colonization
of Eubacterium hallii in the simulated mucus layer.
3.5. Effect of Fermented cRG-I on Intestinal Epithelial Barrier (Test 4)
As cRG-I fermentation enriched several health-associated species and increased production of
SCFA, it might exert favorable effects at the host level. To address this question, a Caco-2/PBMC
co-culture model was developed. Inflammation-induced barrier disruption was obtained upon 48 h
co-culturing of Caco-2 cells with PWM-activated PBMCs and measured as a significant decrease in
TEER of the Caco-2 monolayers (Figure S1A). In addition, apical treatment with the positive control
sodium butyrate (NaB) prevented this TEER decrease. Likewise, apical treatment with fermented cRG-I
showed a significant increase in TEER compared to the blank controls (Figure 6A). Furthermore, effects
on T-cell dependent cytokine production were assessed. As shown in Figure S1, NaB significantly
decreased the secretion of interferon (IFN)γ, interleukin (IL)-17A, IL-21, IL-4, and IL-9; while increasing
the secretion of IL-22; a cytokine involved in maintenance of barrier integrity, wound healing and
antimicrobial responses [53]. However, in contrast to its positive effects on IL-10 secretion in the
Caco-2/THP1 co-culture assay [29], NaB significantly decreased IL-10 secretion possibly due to toxicity
of NaB on IL-10 producing cells at the concentration used [54,55]. Compared to the blank control,
fermented cRG-I reduced the secretion of IL-17A, IL-4, and IL-9; reaching statistical significance
for IL-17A and IL-4 upon luminal incubations and upon both incubations for IL-9 (Figure 6D,F,G).
Furthermore, luminal fermentation of cRG-I tended to increase the secretion of IL-22 and IL-10; of which
the latter was already increased upon treatment with the blank controls (Figure 6E,H). In addition,
all colonic suspensions completely abolished PWM-induced IL-21 secretion (Figure 6C); while no
significant differences were observed on IFNγ secretion (Figure 6B). Hence, metabolites generated
from colonic fermentation of cRG-I displayed anti-inflammatory and gut barrier protective properties.
Figure 6. Effect of fermented cRG-I on transepithelial electrical resistance (TEER) and cytokine
production in a Caco-2/PBMC co-culture system. Caco-2 cells, cultured 14 days on transwell inserts,
were placed on top of pokeweed mitogen (PWM)-activated PBMCs and incubated for 48 h at the apical
side with blank or treatment samples collected during the colonic batch incubations containing only
a luminal (L) or also a mucosal (M) environment. Average (±SEM) TEER of the Caco-2 monolayers
(A) and concentration of secreted interferon (IFN)γ (B), interleukin (IL)-17A (C), IL-21 (D), IL-22 (E),
IL-4 (F), IL-9 (G) and IL-10 (H) in the basolateral medium are shown (n = 3). Statistically significant
differences to PWM are represented by (*). (*) = p < 0.05, (**) = p < 0.01, (***) = p < 0.001.
Overall, some minor effects of the incorporation of a mucosal compartment were observed as
both blank and treatment colonic suspensions slightly increased TEER; while decreased the secretion
of all tested cytokines compared to luminal suspensions (Figure 6).
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4. Discussion
In the current study, novel in vitro models and analytical techniques were implemented to
investigate whether cRG-I classifies as a potential prebiotic ingredient. First, upon exposure to
α-amylase and brush border enzymes (Test 1), unlike the positive controls (cooked starch and maltose,
respectively), cRG-I (like the negative control inulin) was not digested to any of the simple sugars
measured. This suggests that cRG-I can be considered to be a polysaccharide that likely escapes upper
GIT digestion in vivo, thus fulfilling the definition of a prebiotic ingredient that should reach the colon
where it could be fermented by the gut microbiota. Secondly, a recently described short-term colonic
incubation strategy [29] was upgraded with a simulation of the mucosal microbiota (Test 3). By applying
a novel technique to analyze the microbial community composition, i.e., quantitative 16S-targeted
Illumina sequencing [33], in-depth quantitative information was obtained at high phylogenetic
resolution. Besides elucidating treatment effects of cRG-I, this allowed to validate the implementation
of mucin-coated carriers in the short-term incubations by demonstrating a relevant species-specific
colonization of the mucosal environment. Indeed, consistent with the well-established long-term
M-SHIME® model [12], a wide spectrum of (potential butyrate-producing) Firmicutes members
specifically colonized the mucosal environment (e.g., OTUs related to Clostridium butyricum and
Roseburia hominis). Furthermore, inclusion of the mucosal environment did not alter the luminal
microbiota (except for a minor enrichment in Akkermansiaceae), nor did it alter the treatment effects
towards luminal microbiota activity and community composition. Overall, including the mucin beads
in the current colonic simulations allowed to maintain a higher diversity, thus allowing observation of
more complete treatment effects of cRG-I. Finally, application of a model combining gut epithelial and
immune cells allowed to point out the gut protective effect of cRG-I fermentation-derived metabolites
against an inflammatory stressor (Test 4).
In a first series of short-term colonic incubations (Test 2), cRG-I was found to display prebiotic
potential comparable but not identical to that of inulin in modulating microbial activity [19], as followed
from increases in health-promoting SCFA (acetate and propionate) and lactate and decreases of bCFA.
A side effect of inulin fermentation is the production of high amounts of gas that has been observed
in in vitro experiments and clinical studies. Depending on the dose, this can result in mild negative
gastro-intestinal symptoms [56–58]. Interestingly, gas production upon dosing of cRG-I was milder
compared to inulin, which suggests that in vivo consumption of cRG-I could be less accompanied by
adverse side-effects such as bloating and abdominal pain.
Upon fermentation in both short-term colonic incubations (Tests 2/3), cRG-I stimulated acetate,
and lactate production which was accompanied with a strong reduction in pH. At community level,
this correlated with increases in OTUs related to Bifidobacterium longum (OTU7) and Bifidobacterium
adolescentis (OTU21). Bifidobacteriaceae are indeed key acetate and lactate producers [59,60]. Although
health effects are to be considered strain-specific, multiple Bifidobacterium strains have been associated
with beneficial effects on the host health and some strains are widely used as probiotics. A first
mechanism by which Bifidobacteriaceae contribute to health is by indirectly promoting butyrate
production via cross-feeding mechanisms involving for instance Faecalibacterium prausnitzii and
Eubacterium hallii [59,61,62], taxa of which related OTUs were indeed found to be increased upon cRG-I
treatment in the current study. In addition, acetate produced by bifidobacteria was also shown to
play a key role in their anti-infectious properties against enteropathogens [63]. In terms of host effects,
a specific B. longum strain has e.g., been shown to exert protective effects in a DSS-induced colitis
model in mice by reducing inflammation and enhancing the intestinal epithelial barrier [64]. Moreover,
a specific B. longum strain reduced chronic mucosal inflammation in ulcerative colitis (UC) patients in
a double-blinded, randomized-controlled clinical trial [65]. Likewise, a specific B. adolescentis strain
protected mice from DSS-induced colitis by increasing IL-10 levels, up-regulation of regulatory T-cells
(Treg) and decreasing IL-17A positive T-cells [66]. The strong bifidogenic effect exerted by cRG-I thus
supports the prebiotic potential of this novel food ingredient.
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Next to acetate and lactate, fermentation of cRG-I increased the production of propionate, which
correlated with a stimulation of Prevotellaceae and Bacteroidaceae due to the stimulation of a wide spectrum
of Bacteroidaceae OTUs related to e.g., B. ovatus, B. plebeius, B. xylanisolvens and especially B. dorei. Indeed,
Bacteriodetes spp. are known primary fiber degraders that are capable of producing propionate [50].
In the colon, health-related effects of propionate are related to anti-cancer effects [7,8]. Furthermore,
propionate was shown to exert anti-lipogenic and cholesterol-lowering effects in the liver [6]. Finally,
propionate is a satiety-inducing agent affecting energy intake and feeding behavior [67]. Besides the
beneficial effects of propionate, the aforementioned stimulations of specific Bacteroidaceae members
have also been related to particular health benefits. As an example, in a mouse model of atherosclerosis,
B. dorei reduced plaque inflammation and decreased intestinal epithelial permeability and systemic
endotoxemia [68]. Furthermore, B. ovatus reduced mucosal inflammation and stimulated epithelial
proliferation and mucin production in a DSS-induced colitis model in mice [69]. Another microbial
modulation that could have boosted propionate production upon cRG-I treatment was the increase
in Veillonellaceae that was solely attributed to an increase in OTU9 (related to Dialister succinatiphilus).
Interestingly, D. succinatiphilus is a succinate-converting, propionate-producing species [70] and as
many Bacteroidetes spp. are known succinate producers [50], its increase might have contributed to the
stronger increase in propionate levels upon dosing of cRG-I. As a final remark, not all Bacteroidaceae
members increased upon cRG-I treatment, with OTUs relating to B. caccae and B. fragilis decreasing in
abundance upon cRG-I treatment. These species are considered to be opportunistic pathogens carrying
virulence factors: enterotoxigenic B. fragilis strains secrete the B. fragilis toxin (BFT) [71] and B. caccae
contains the ompW gene [72]. Besides its strong bifidogenic effect, cRG-I could further exert health
benefits by targeted modulation of specific propionate-producing taxa.
In contrast to propionate, butyrate was not significantly increased upon dosing of cRG-I. However,
cRG-I did strongly stimulate Lachnospiraceae, containing several butyrate-producing species, in the
mucosal compartment. The increase in Lachnospiraceae was related to a strong stimulation of an OTU
related to Roseburia hominis, which has been associated with beneficial effects on barrier function and
immune regulation in the gut [73]. Indeed, R. hominis showed protective effects in a DSS-model for
colitis in mice by reducing pro-inflammatory cytokine expression. Moreover, increased Treg levels were
observed in both germ-free and conventional mice fed a supplement containing live R. hominis. Also,
a significant reduction of R. hominis and F. prausnitzii was observed in UC and Crohn’s disease (CD)
patients [74,75]. Interestingly, cRG-I increased the abundance of OTUs related to butyrate-producing
species such as F. prausnitzii and Eubacterium hallii. Like R. hominis, F. prausnitzii was shown to
exert anti-inflammatory potential by increasing IL-10 and promoting Treg differentiation in mice [76].
On the other hand, E. hallii improved insulin sensitivity in a mouse model for diabetes [77]. Of note,
discrepancy between the stimulation of butyrate producers in the mucosal environment with cRG-I
versus the absence of treatment effects on butyrate levels might be explained by the fact that the biofilm
which develops on the mucin-coated carriers during short-term colonic incubations (48 h) is still
developing during cRG-I treatment. Hence, by the time the biofilm is developed (48 h), all substrate
has been consumed (in fact already after 24 h). This may potentially limit the detection of treatment
effects resulting from modulation of mucosal microbes on metabolic activity (particularly butyrate
production) during short-term incubations. Therefore, testing the impact of cRG-I in a long-term
M-SHIME® study could further elucidate the potential impact of cRG-I on butyrate production.
The stimulation of several health-related microbial species and the concomitant increase in
health-promoting metabolites suggested that cRG-I may display interesting host beneficial properties
in terms of intestinal barrier protection and reduction of inflammation. This hypothesis was confirmed
using a Caco-2/PBMC co-culture model in which treatment with fermented cRG-I significantly
increased the TEER, indicative for the protective effects of fermentation-derived cRG-I metabolites
on inflammation-induced intestinal permeability. To further strengthen this observation, it would be
interesting to perform in-depth analysis of the expression and localization of tight junction proteins
including occludin, ZO-1, and claudins upon cRG-I treatment in this system. Furthermore, fermented
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cRG-I metabolites decreased the secretion of the pro-inflammatory cytokines IL-17A, IL-4, and IL-9,
while increasing the secretion of IL-22 and of the anti-inflammatory IL-10. This is suggestive of a possible
immunoregulatory effect of cRG-I metabolites on the Treg/TH17 axis; favoring down-regulation of
excessive inflammation as IL-10 is necessary for Treg functions [78]. Th17 cells have a dual role in
human health as although required for clearance of extracellular pathogens, an elevated frequency of
Th17 cells associated with impaired Treg functions has been reported in IBD and other extraintestinal
autoimmune disorders [79]. Furthermore, IL-22 plays a role in maintaining the integrity of the mucosal
barrier by promoting wound healing and activating antimicrobial responses [53]. Finally, increased
levels of IL-4 and IL-9 were associated with UC [80,81]. In addition, IL-9 inhibits wound healing in the
intestinal mucosa and impairs intestinal epithelial barrier functions. Also, IL-9 directly regulates tissue
recruitment and inflammatory functions of mast cells. Together, these data suggest an interesting
immuno-modulatory role of cRG-I metabolites in the gut in terms of increasing barrier tightness and
prevention of a “leaky gut”.
Finally, a modified formulation of cRG-I was tested which contained small size sugars, i.e.,
cRG-I+LMWC. Interestingly, the short-term colonic incubation strategy applied in this study was
highly sensitive to pick up differences in closely related product compositions. For instance, the presence
of these simple sugars resulted in a stronger initial pH decrease upon dosing of cRG-I+LMWC, related
to an initial increased production of lactate, which could be linked to a stronger enrichment in
a Streptococcacae OTU related to Streptococcus aginosus. Also, Enterobacteriaceae levels were higher
upon cRG-I+LMWC treatment. Like Streptococcaceae, Enterobacteriaceae are expert fermenters of
simple sugars [82], specifically present at higher levels in this preparation. Finally, Coriobacteriaceae
(OTU15 related to Collinsella aerofaciens) and Desulfovibrionaceae tended to be higher in incubations with
cRG-I+LMWC. This suggested a potential co-existence of e.g., C. aerofaciens and Desulfovibrio piger,
based on the fact that the main products of C. aerofaciens fermentation (i.e., lactate, H2, and formate)
serve as substrates for D. piger, which is the main sulfate-reducing bacterial species in the human
gut microbiome [83]. This might also indicate that cRG-I+LMWC might contain small quantities of
sulfur (sulfate or sulfur-containing amino acids). These data altogether stress the relevance of testing
prebiotic candidates in short-term colonic in vitro incubations to understand their potential impact on
the human gut microbiome and to support structure-function studies.
In conclusion, the implementation of novel in vitro models simulating the human colonic
environment coupled to cell-based assays mimicking the host gut barrier, allowed to establish the
prebiotic potential of cRG-I. This novel fiber is not digested by host enzymes characteristic of the upper
gastro-intestinal tract but rapidly fermented by the human colonic microbiota leading to selective
stimulation of the growth and activity of intestinal bacterial species associated with human health.
cRG-I displays unique properties as it was fermented more rapidly than inulin leading to production
of SCFA, especially acetate and propionate, and less gas than inulin. It increases the abundance of
several bacterial species reputed for their “anti-inflammatory” profile. In line with this, the metabolites
resulting from cRG-I fermentation exhibited a protective effect in an in vitro model of inflamed gut
barrier. Overall, the data obtained during this study support future research to further investigate
this novel prebiotic candidate in long-term SHIME® models with different fecal sample donors and in
clinical trials to confirm the beneficial effect of cRG-I on the microbiota and its impact on human health.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/7/1917/s1,
Figure S1: Effect of Sodium butyrate (NaB) on transepithelial electrical resistance (TEER) and cytokine production
in a Caco-2/PBMC co-culture system; Table S1: Effect of fermentation of cRG-I and cRG-I+LMWC on microbial
community composition at OTU level in short-term colonic batch simulations in absence or presence of a mucosal
compartment; Table S2: Effect of fermentation of cRG-I and cRG-I+LMWC on selected bacterial groups in
short-term colonic batch simulations in absence or presence of a mucosal compartment as assessed through qPCR.
Author Contributions: Conceptualization, A.M., P.v.d.A., M.M.; Methodology, P.v.d.A.; Formal Analysis, J.G., L.V.;
Investigation, J.G., L.V.; Data Curation, P.v.d.A., L.V., J.G.; Writing-Original Draft Preparation, A.M.; P.v.d.A., L.V.
Writing-Review and Editing, A.M., R.A., P.v.d.A., L.V.; Supervision, P.v.d.A., M.M.; Project Administration, M.M.;
Funding Acquisition, A.M., R.A. All authors have read and agreed to the published version of the manuscript.
Nutrients 2020, 12, 1917 17 of 21
Funding: The studies described in this manuscript were performed at the request of and were funded by NutriLeads
B.V., Wageningen, The Netherlands. This project has received funding from the European Union’s Horizon 2020
research and innovation programme under grant agreements No 811592 and Eurostars E! 10574-NIMF.
Acknowledgments: We thank C. Rösch and H. Schols for their expert advice in the preparation of the cRG-I
formulations and sugar analysis. We acknowledge the support of M. Aparicio-Vergara and M. Tzoumaki in
performing preliminary work to the experiments.
Conflicts of Interest: A.M. and R.A. are employees of Nutrileads the funder of the study. A.M. participated to the
design of the study and the writing of the manuscript. R.A. edited the manuscript.
References
1. Forgie, A.J.; Fouhse, J.M.; Willing, B.P. Diet-Microbe-Host Interactions That Affect Gut Mucosal Integrity and
Infection Resistance. Front. Immunol. 2019, 10, 1802. [CrossRef]
2. Monteagudo-Mera, A.; Rastall, R.A.; Gibson, G.R.; Charalampopoulos, D.; Chatzifragkou, A. Adhesion
mechanisms mediated by probiotics and prebiotics and their potential impact on human health. Appl. Microbiol.
Biotechnol. 2019, 103, 6463–6472. [CrossRef]
3. Kachrimanidou, M.; Tsintarakis, E. Insights into the Role of Human Gut Microbiota in Clostridioides difficile
Infection. Microorganisms 2020, 8, 200. [CrossRef]
4. Hooper, L.V.; Midtvedt, T.; Gordon, J.I. How host-microbial interactions shape the nutrient environment of
the mammalian intestine. Annu. Rev. Nutr. 2002, 22, 283–307. [CrossRef]
5. Liu, H.; Wang, J.; He, T.; Becker, S.; Zhang, G.; Li, D.; Ma, X. Butyrate: A Double-Edged Sword for Health?
Adv. Nutr. 2018, 9, 21–29. [CrossRef] [PubMed]
6. Delzenne, N.M.; Williams, C.M. Prebiotics and lipid metabolism. Curr. Opin. Lipidol. 2002, 13, 61–67. [CrossRef]
[PubMed]
7. Li, C.J.; Elsasser, T.H. Butyrate-induced apoptosis and cell cycle arrest in bovine kidney epithelial cells:
Involvement of caspase and proteasome pathways. J Anim. Sci. 2005, 83, 89–97. [CrossRef]
8. Jan, G.; Belzacq, A.S.; Haouzi, D.; Rouault, A.; Métivier, D.; Kroemer, G.; Brenner, C. Propionibacteria induce
apoptosis of colorectal carcinoma cells via short-chain fatty acids acting on mitochondria. Cell Death Differ.
2002, 9, 179–188. [CrossRef]
9. Lin, Y.G.; Vonk, R.J.; Slooff, M.J.H.; Kuipers, F.; Smit, M.J. Differences in propionate-induced inhibition of
cholesterol and triacylglycerol synthesis between human and rat hepatocytes in primary culture. Br. J. Nutr.
1995, 74, 197–207. [CrossRef]
10. Nishina, P.M.; Freedland, R.A. Effects of propionate on lipid biosynthesis in isolated rat hepatocytes. J. Nutr.
1990, 120, 668–673. [CrossRef]
11. Rinninella, E.; Raoul, P.; Cintoni, M.; Franceschi, F.; Miggiano, G.A.D.; Gasbarrini, A.; Mele, M.C. What is the
Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases.
Microorganisms 2019, 7, 14. [CrossRef] [PubMed]
12. Van den Abbeele, P.; Belzer, C.; Goossens, M.; Kleerebezem, M.; De Vos, W.M.; Thas, O.; De Weirdt, R.;
Kerckhof, F.M.; Van de Wiele, T. Butyrate-producing Clostridium cluster XIVa species specifically colonize
mucins in an in vitro gut model. ISME J. 2013, 7, 949–961. [CrossRef] [PubMed]
13. Eckburg, P.B.; Bik, E.M.; Bernstein, C.N.; Purdom, E.; Dethlefsen, L.; Sargent, M.; Gill, S.R.; Nelson, K.E.;
Relman, D.A. Diversity of the human intestinal microbial flora. Science 2005, 308, 1635–1638. [CrossRef]
[PubMed]
14. Frank, D.N.; Amand, A.L.S.; Feldman, R.A.; Boedeker, E.C.; Harpaz, N.; Pace, N.R. Molecular-phylogenetic
characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl.
Acad. Sci. USA 2007, 104, 13780–13785. [CrossRef]
15. Shen, X.J.; Rawls, J.F.; Randall, T.A.; Burcall, L.; Mpande, C.; Jenkins, N.; Jovov, B.; Abdo, Z.; Sandler, R.S.;
Keku, T.O. Molecular characterization of mucosal adherent bacteria and associations with colorectal adenomas.
Gut Microbes 2010, 1, 138–147. [CrossRef]
16. Wang, Y.; Antonopoulos, D.; Zhu, X.; Harrell, L.; Hanan, I.; Alverdy, J.; Meyer, F.; Musch, M.W.; Young, V.B.;
Chang, E.B. Laser capture microdissection and metagenomic analysis of intact mucosa-associated microbial
communities of human colon. Appl. Environ. Microbiol. 2010, 88, 1333–1342. [CrossRef] [PubMed]
Nutrients 2020, 12, 1917 18 of 21
17. Willing, B.P.; Dicksved, J.; Halfvarson, J.; Andersson, A.F.; Lucio, M.; Zheng, Z.; Järnerot, G.; Tysk, C.;
Jansson, J.K.; Engstrand, L. A pyrosequencing study in twins shows that gastrointestinal microbial profiles
vary with inflammatory bowel disease phenotypes. Gastroenterology 2010, 139, 1844–1854. [CrossRef]
18. Hong, P.-Y.; Croix, J.A.; Greenberg, E.; Gaskins, H.R.; Mackie, R.I. Pyrosequencing-based analysis of the
mucosal microbiota in healthy individuals reveals ubiquitous bacterial groups and micro-heterogeneity.
PLoS ONE 2011, 6, e25042. [CrossRef]
19. Gibson, G.R.; Hutkins, R.; Sanders, M.E.; Prescott, S.L.; Reimer, R.A.; Salminen, S.J.; Scott, K.; Stanton, C.;
Swanson, K.S.; Cani, P.D.; et al. Expert consensus document: The International Scientific Association for
Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev.
Gastroenterol. Hepatol. 2017, 14, 491–502. [CrossRef]
20. Minekus, M.; Alminger, M.; Alvito, P.; Balance, S.; Bohn, T.; Bourlieu, C.; Carrière, F.; Boutrou, R.;
Corredig, M.; Dupont, D.; et al. A standardised static in vitro digestion method suitable for food—An
international consensus. Food Funct. 2014, 5, 1113–1124. [CrossRef]
21. Hodoniczky, J.; Morris, C.A.; Rae, A.L. Oral and intestinal digestion of oligosaccharides as potential
sweeteners: A systematic evaluation. J. Food Chem. 2012, 132, 1951–1958. [CrossRef]
22. Sonnenburg, E.D.; Zheng, H.; Joglekar, P.; Higginbottom, S.K.; Firbank, S.J.; Bolam, D.N.; Sonnenburg, J.L.
Specificity of polysaccharide use in intestinal bacteroides species determines diet-induced microbiota
alterations. Cell 2010, 141, 1241–1252. [CrossRef] [PubMed]
23. Hiippala, K.; Kainulainen, V.; Suutarinen, M.; Heini, T.; Bowers, J.R.; Jasso-Selles, D.; Lemmer, D.; Valentine, M.;
Barnes, R.; Engelthaler, D.M.; et al. Isolation of Anti-Inflammatory and Epithelium Reinforcing Bacteroides
and Parabacteroides Spp. from A Healthy Fecal Donor. Nutrients 2020, 12, E935. [CrossRef] [PubMed]
24. Coenen, G.J.; Bakx, E.; Verhoef, R.P.; Schols, H.A.; Voragen, A. Identification of the connecting linkage
between homo- or xylogalacturonan and rhamnogalacturonan type I. Carbohydrate. Polymers 2007, 70,
224–235.
25. Wu, D.; Zheng, J.; Mao, G.; Hu, W.; Ye, X.; Linhardt, R.J.; Chen, S. Rethinking the impact of RG-I mainly from
fruits and vegetables on dietary health. Crit. Rev. Food Sci. Nutr. 2019, 1–23. [CrossRef]
26. Chakaroun, R.M.; Massier, L.; Kovacs, P. Gut Microbiome, Intestinal Permeability, and Tissue Bacteria in
Metabolic Disease: Perpetrators or Bystanders? Nutrients 2020, 12, E1082. [CrossRef]
27. Marzorati, M.; Pinheiro, I.; Van den Abbeele, P.; Van de Wiele, T.; Possemiers, S. An in vitro technology
platform to assess host microbiota interactions in the gastrointestinal tract. Agro Food Ind. Hi Tech 2013, 23,
8–11.
28. Satsu, H.; Ishimoto, Y.; Nakano, T.; Mochizuki, T.; Iwanaga, T.; Shimizu, M. Induction by activated
macrophage-like THP-1 cells of apoptotic and necrotic cell death in intestinal epithelial Caco-2 monolayers
via tumor necrosis factor-alpha. Exp. Cell Res. 2006, 312, 3909–3919. [CrossRef]
29. Van den Abbeele, P.; Taminiau, B.; Pinheiro, I.; Duysburgh, C.; Jacobs, H.; Pijls, L.; Marzorati, M.
Arabinoxylo-Oligosaccharides and Inulin Impact Inter-Individual Variation on Microbial Metabolism
and Composition, Which Immunomodulates Human Cells. J. Agric. Food Chem. 2018, 66, 1121–1130.
[CrossRef] [PubMed]
30. Daguet, D.; Pinheiro, I.; Verhelst, A.; Possemiers, S.; Marzorati, M. Arabinogalactan and fructooligosaccharides
improve the gut barrier function in distinct areas of the colon in the Simulator of the Human Intestinal
Microbial Ecosystem. J. Funct. Foods 2016, 20, 369–379. [CrossRef]
31. Possemiers, S.; Pinheiro, I.; Verhelst, A.; Van den Abbeele, P.; Maignien, L.; Laukens, D.; Reeves, S.G.;
Robinson, L.E.; Raas, T.; Schneider, Y.-J.; et al. A dried yeast fermentate selectively modulates both the
luminal and mucosal gut microbiota and protects against inflammation, as studied in an integrated in vitro
approach. J. Agric. Food Chem. 2013, 61, 9380–9392. [CrossRef] [PubMed]
32. Kleiveland, C.R. Peripheral Blood Mononuclear Cells. In The Impact of Food Bioactives on Health: In vitro and
Ex Vivo Models; Verhoeckx, K., Cotter, P., López-Expósito, I., Kleiveland, C., Lea, T., Mackie, A., Requena, T.,
Swiatecka, D., Wichers, H., Eds.; Springer Cham (CH): Cham, Switzerland, 2015; Chapter 15.
33. Van den Abbeele, P.; Moens, F.; Pignataro, G.; Schnurr, J.; Ribecco, C.; Gramenzi, A.; Marzorati, M.
Yeast-Derived Formulations Are Differentially Fermented by the Canine and Feline Microbiome As Assessed
in a Novel In Vitro Colonic Fermentation Model. J. Agric. Food Chem. 2020. [CrossRef] [PubMed]
Nutrients 2020, 12, 1917 19 of 21
34. Jonker, D.; Fowler, P.; Albers, R.; Tzoumaki, M.V.; van het Hof, K.H.; Aparicio-Vergara, M. Safety assessment
of rhamnogalacturonan-enriched carrot pectin fraction: 90-day oral toxicity study in rats and in vitro
genotoxicity studies. Food Chem. Toxicol. 2020, 139, 111243. [CrossRef]
35. De Weirdt, R.; Possemiers, S.; Vermeulen, G.; Moerdijk-Poortvliet, T.C.W.; Boschker, H.T.S.; Verstraete, W.;
Van de Wiele, T. Human faecal microbiota display variable patterns of glycerol metabolism. FEMS Microbiol.
Ecol. 2010, 74, 601–611. [CrossRef] [PubMed]
36. Boon, N.; Top, E.M.; Verstraete, W.; Siciliano, S.D. Bioaugmentation as a tool to protect the structure and
function of an activated-sludge microbial community against a 3-chloroaniline shock load. Appl. Environ.
Microbiol. 2003, 69, 1511–1520. [CrossRef]
37. Furet, J.P.; Firmesse, O.; Gourmelon, M.; Bridonneau, C.; Tap, J.; Mondot, S.; Doré, J.; Corthier, G. Comparative
assessment of human and farm animal faecal microbiota using real-time quantitative PCR. FEMS Microbiol.
Ecol. 2009, 68, 351–362. [CrossRef]
38. Rinttilä, T.; Kassinen, A.; Malinen, E.; Kroqius, L.; Palva, A. Development of an extensive set of 16S
rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by
real-time PCR. J. Appl. Microbiol. 2004, 97, 1166–1177. [CrossRef]
39. Collado, M.C.; Derrien, M.; Isolauri, E.; de Vos, W.M.; Salminen, S. Intestinal integrity and Akkermansia
muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the
elderly. Appl. Environ. Microbiol. 2007, 23, 7767–7770. [CrossRef]
40. Guo, X.; Xia, X.; Tang, R.; Zhou, J.; Zhao, H.; Wang, K. Development of a real-time PCR method for Firmicutes
and Bacteroidetes in faeces and its application to quantify intestinal population of obese and lean pigs.
Lett. Appl. Microbiol. 2008, 47, 367–373. [CrossRef]
41. Nakano, S.; Kobayashi, T.; Funabiki, K.; Matsumura, A.; Nagao, Y.; Yamada, T. Development of a PCR assay
for detection of Enterobacteriaceae in foods. J. Food Prot. 2003, 66, 1798–1804. [CrossRef]
42. Sokol, H.; Seksik, P.; Furet, J.P.; Firmesse, O.; Nion-Larmurier, I.; Beaugerie, L.; Cosnes, J.; Corthier, G.;
Marteau, P.; Doré, J. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm. Bowel Dis.
2009, 15, 1183–1189. [CrossRef] [PubMed]
43. Ramirez-Farias, C.; Slezak, K.; Fuller, Z.; Duncan, A.; Holtrop, G.; Louis, P. Effect of inulin on the human gut
microbiota: Stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br. J. Nutr. 2009,
101, 541–550. [CrossRef] [PubMed]
44. Props, R.; Kerckhof, F.-M.; Rubbens, P.; De Vrieze, J.; Hernandez Sanabria, E.; Waegeman, W.; Monsieurs, P.;
Hammes, F.; Boon, N. Absolute quantification of microbial taxon abundances. ISME J. 2017, 11, 584–587.
[CrossRef] [PubMed]
45. Klindworth, A.; Pruesse, E.; Schweer, T.; Peplies, J.; Quast, C.; Horn, M.; Glöckner, F.O. Evaluation of general
16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studies.
Nucleic Acids Res. 2013, 41, e1. [CrossRef] [PubMed]
46. Schloss, P.D.; Westcott, S.L. Assessing and improving methods used in operational taxonomic unit-based
approaches for 16S rRNA gene sequence analysis. Appl. Environ. Microbiol. 2011, 77, 3219–3226. [CrossRef]
47. Kozich, J.J.; Westcott, S.L.; Baxter, N.T.; Highlander, S.K.; Schloss, P.D. Development of a dual-index
sequencing strategy and curation pipeline for analyzing amplicon sequence data on MiSeq Illumina
sequencing platform. Appl. Environ. Microbiol. 2013, 79, 5112–5120. [CrossRef]
48. Wang, Q.; Garrity, G.M.; Tiedje, J.M.; Cole, J.R. Naive Bayesian classifier for rapid assignment of rRNA
sequences into the new bacterial taxonomy. Appl. Environ. Microbiol. 2007, 73, 5261–5267. [CrossRef]
49. Cole, J.R.; Wang, Q.; Cardenas, E.; Fish, J.; Chai, B.; Farris, R.J.; Kulam-Syed-Mohideen, A.S.; McGarrell, D.M.;
Marsh, T.; Garrity, G.M.; et al. The ribosomal database project: Improved alignments and new tools for
rRNA analysis. Nucleic Acids Res 2009, 37, D141–D145. [CrossRef]
50. Louis, P.; Flint, H.J. Formation of propionate and butyrate by the human colonic microbiota. Environ. Microbiol.
2017, 19, 29–41. [CrossRef]
51. Hamer, H.M.; De Preter, V.; Windey, K.; Verbeke, K. Functional analysis of colonic bacterial metabolism:
Relevant to health. Am. J. Physiol. Liver Physiol. 2012, 302, G1–G9. [CrossRef]
52. Scott, K.P.; Gratz, S.W.; Sheridan, P.O.; Flint, H.J.; Duncan, S.H. The influence of diet on the gut microbiota.
Pharmacol. Res. 2013, 69, 52–60. [CrossRef] [PubMed]
53. Kempski, J.; Brockmann, L.; Gagliani, N.; Huber, S. TH17 Cell and Epithelial Cell Crosstalk during
Inflammatory Bowel Disease and Carcinogenesis. Front Immunol. 2017, 8, 1373. [CrossRef]
Nutrients 2020, 12, 1917 20 of 21
54. Kurita-Ochiai, T.; Fukushima, K.; Ochiai, K. Lipopolysaccharide stimulates butyric acid-induced apoptosis
in human peripheral blood mononuclear cells. Infect. Immun. 1999, 67, 22–29. [CrossRef] [PubMed]
55. Weber, T.E.; Kerr, B.J. Butyrate differentially regulates cytokines and proliferation in porcine peripheral blood
mononuclear cells. Vet. Immunol. Immunopathol. 2006, 113, 139–147. [CrossRef] [PubMed]
56. Bonnema, A.L.; Kolberg, L.W.; Thomas, W.; Slavin, J.L. Gastrointestinal tolerance of chicory inulin products.
J. Am. Diet. Assoc. 2010, 110, 865–868. [CrossRef]
57. Timm, D.A.; Stewart, M.L.; Hospattankar, A.; Slavin, J.L. Wheat Dextrin, Psyllium, and Inulin Produce
Distinct FermentationPatterns, GasVolumes, andShort-Chain Fatty AcidProfiles InVitro. J. Med. Food 2010,
13, 961–996. [CrossRef]
58. Carlson, J.L.; Erickson, J.M.; Hess, J.M.; Gould, T.J.; Slavin, J.L. Prebiotic Dietary Fiber and Gut Health:
Comparing the in Vitro Fermentations of Beta-Glucan, Inulin and Xylooligosaccharide. Nutrients 2017,
9, 1361. [CrossRef]
59. Belenguer, A.; Duncan, S.H.; Calder, A.G.; Holtrop, G.; Louis, P.; Lobley, G.E.; Flint, H.J. Two Routes of
Metabolic Cross-Feeding between Bifidobacterium adolescentis and Butyrate-Producing Anaerobes from the
Human Gut. Appl. Environ. Microbiol. 2006, 72, 3593–3599. [CrossRef]
60. De Vuyst, L.; Moens, F.; Selak, M.; Rivière, A.; Leroy, F. Summer Meeting 2013: Growth and physiology of
bifidobacteria. J. Appl. Microbiol. 2014, 116, 477–491. [CrossRef]
61. Milani, C.; Lugli, G.A.; Duranti, S.; Turroni, F.; Mancabelli, L.; Ferrario, C.; Mangifesta, M.; Hevia, A.;
Viappiani, A.; Scholz, M.; et al. Bifidobacteria exhibit social behavior through carbohydrate resource sharing
in the gut. Sci. Rep. 2015, 5, 15782. [CrossRef]
62. Moens, F.; Weckx, S.; De Vuyst, L. Bifidobacterial inulin-type fructan degradation capacity determines
cross-feeding interactions between bifidobacteria and Faecalibacterium prausnitzii. Int. J. Food Microbiol.
2016, 231, 76–85. [CrossRef] [PubMed]
63. Fukuda, S.; Toh, H.; Hase, K.; Oshima, K.; Nakanishi, Y.; Yoshimura, K.; Tobe, T.; Clarke, J.M.; Topping, D.L.;
Suzuki, T.; et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate.
Nature 2011, 469, 543–547. [CrossRef] [PubMed]
64. Srutkova, D.; Schwarzer, M.; Hudcovic, T.; Zakostelska, Z.; Drab, V.; Spanova, A.; Rittich, B.; Kozakova, H.;
Schabussova, I. Bifidobacterium longum CCM 7952 Promotes Epithelial Barrier Function and Prevents Acute
DSS-Induced Colitis in Strictly Strain-Specific Manner. PLoS ONE 2015, 10, e0134050. [CrossRef] [PubMed]
65. Furrie, E.; Macfarlane, S.; Kennedy, A.; Cummings, J.H.; Walsh, S.V.; O’neil, D.A.; Macfarlane, G.T. Synbiotic
therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active
ulcerative colitis: A randomised controlled pilot trial. Gut 2005, 54, 242–249. [CrossRef]
66. Yu, R.; Zuo, F.; Ma, H.; Chen, S. Exopolysaccharide-Producing Bifidobacterium adolescentis Strains with
Similar Adhesion Property Induce Differential Regulation of Inflammatory Immune Response in Treg/Th17
Axis of DSS-Colitis Mice. Nutrients 2019, 11, E782. [CrossRef] [PubMed]
67. Hosseini, E.; Grootaert, C.; Verstraete, W.; Van de Wiele, T. Propionate as a health-promoting microbial
metabolite in the human gut. Nutr. Rev. 2011, 69, 245–258. [CrossRef] [PubMed]
68. Yoshida, N.; Emoto, T.; Yamashita, T.; Watanabe, H.; Hayashi, T.; Tabata, T.; Hoshi, N.; Hatano, N.; Ozawa, G.;
Sasaki, N.; et al. Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide
Production and Inhibit Atherosclerosis. Circulation 2018, 138, 2486–2498. [CrossRef]
69. Ihekweazu, F.D.; Fofanova, T.Y.; Queliza, K.; Nagy-Szakal, D.; Stewart, C.J.; Engevik, M.A.; Hulten, K.G.;
Tatevian, N.; Graham, D.Y.; Versalovic, J.; et al. Bacteroides ovatus ATCC 8483 monotherapy is superior to
traditional fecal transplant and multi-strain bacteriotherapy in a murine colitis model. Gut Microbes 2019, 10,
504–520. [CrossRef] [PubMed]
70. Morotomi, M.; Nagai, F.; Sakon, H.; Tanaka, R. Dialister succinatiphilus sp. nov. and Barnesiella
intestinihominis sp. nov., isolated from human faeces. Int. J. Syst. Evol. Microbiol. 2008, 58, 2716–2720.
[CrossRef]
71. Sears, C.L. Enterotoxigenic Bacteroides fragilis: A rogue among symbiotes. Clin. Microbiol. Rev. 2009, 22,
349–366. [CrossRef]
72. Wei, B.; Dalwadi, H.; Gordon, L.K.; Landers, C.; Bruckner, D.; Targan, S.R.; Braun, J. Molecular cloning of
a Bacteroides caccae TonB-linked outer membrane protein identified by an inflammatory bowel disease
marker antibody. Infect. Immun. 2001, 69, 6044–6054. [CrossRef] [PubMed]
Nutrients 2020, 12, 1917 21 of 21
73. Patterson, A.M.; Mulder, I.E.; Travis, A.J.; Lan, A.; Cerf-Bensussan, N.; Gaboriau-Routhiau, V.; Garden, K.;
Logan, E.; Delday, M.I.; Coutts, A.G.P.; et al. Human Gut Symbiont Roseburia hominis Promotes and
Regulates Innate Immunity. Front. Immunol. 2017, 8, 1166. [CrossRef]
74. Machiels, K.; Joossens, M.; Sabino, J.; De Preter, V.; Arijs, I.; Eeckhaut, V.; Ballet, V.; Claes, K.; Van Immerseel, F.;
Verbeke, K.; et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium
prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 2014, 63, 1275–1283. [CrossRef] [PubMed]
75. Tilg, H.; Danese, S. Roseburia hominis: A novel guilty player in ulcerative colitis pathogenesis? Gut 2014, 63,
1204–1205. [CrossRef] [PubMed]
76. Qiu, X.; Zhang, M.; Yang, X.; Hong, N.; Yu, C. Faecalibacterium prausnitzii upregulates regulatory T cells and
anti-inflammatory cytokines in treating TNBS-induced colitis. J. Crohns Colitis 2013, 7, e558–e568. [CrossRef]
[PubMed]
77. Udayappan, S.; Manneras-Holm, L.; Chaplin-Scott, A.; Belzer, C.; Herrema, H.; Dallinga-Thie, G.M.;
Duncan, S.H.; Stroes, E.S.G.; Groen, A.K.; Flint, H.J.; et al. Oral treatment with Eubacterium hallii improves
insulin sensitivity in db/db mice. NPJ Biofilms Microbiomes 2016, 2, 16009. [CrossRef]
78. Murai, M.; Turovskaya, O.; Kim, G.; Madan, R.; Karp, C.L.; Cheroutre, H.; Kronenberg, M. Interleukin 10 acts
on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in
mice with colitis. Nat. Immunol. 2009, 10, 1178–1184. [CrossRef]
79. Kumar, P.; Monin, L.; Castillo, P.; Elsegeiny, W.; Horne, W.; Eddens, T.; Vikram, A.; Good, M.; Schoenborn, A.A.;
Bibby, K.; et al. Intestinal Interleukin-17 Receptor Signaling Mediates Reciprocal Control of the Gut Microbiota
and Autoimmune Inflammation. Immunity. 2016, 44, 659–671. [CrossRef] [PubMed]
80. Chen, M.L.; Sundrud, M.S. Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases.
Inflamm. Bowel Dis. 2016, 22, 1157–1167. [CrossRef] [PubMed]
81. Wang, Y.H. Developing food allergy: A potential immunologic pathway linking skin barrier to gut.
F1000Research 2016, 5, F1000. [CrossRef] [PubMed]
82. Clark, D.P. The fermentation pathways of Escherichia coli. FEMS Microbiol. Rev. 1989, 5, 223–234. [CrossRef]
83. Rey, F.E.; Gonzalez, M.D.; Cheng, J.; Wu, M.; Ahern, P.P.; Gordon, J.I. Metabolic niche of a prominent
sulfate-reducing human gut bacterium. Proc. Natl. Acad. Sci. USA 2013, 110, 13582–13587. [CrossRef]
[PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
